Latest Treatments for Methamphetamine Use Disorder

Methamphetamine use disorder remains one of the most challenging substance use disorders to treat, with devastating impacts on individuals, families, and communities worldwide. Despite the significant public health burden, the development of effective treatments for methamphetamine use disorder has lagged behind that for other substance use disorders. As we move through 2025 and look toward 2026, the need for effective treatments for methamphetamine use disorder has never been more critical.

The latest treatments for methamphetamine use disorder represent a diverse landscape of approaches, from refinements of established behavioral therapies to innovative pharmacological interventions and novel adjunctive treatments. While there remains no FDA-approved medication specifically for methamphetamine use disorder, recent years have seen significant progress in clinical research that offers new hope for those affected by this condition.

This article provides a comprehensive overview of the current treatment landscape for methamphetamine use disorder in 2025-2026, highlighting both established approaches and emerging innovations that show promise for improving outcomes. By examining the latest treatments for methamphetamine use disorder through an evidence-based lens, we aim to provide healthcare professionals, researchers, and those affected by methamphetamine addiction with a clear understanding of the current state of treatment and future directions.

Behavioral Therapies: Foundation of Treatment

Behavioral interventions remain the cornerstone of treatment for methamphetamine use disorder, with several approaches demonstrating effectiveness in reducing use and supporting recovery. The latest treatments for methamphetamine use disorder continue to build upon these evidence-based behavioral foundations while incorporating new adaptations and delivery methods.

Cognitive Behavioral Therapy (CBT) and Tailored CBT Adaptations

Cognitive Behavioral Therapy continues to be one of the most widely used and effective behavioral treatments for methamphetamine use disorder. In 2025, several tailored adaptations of CBT have emerged that specifically address the unique challenges of methamphetamine addiction:

• Methamphetamine-Specific CBT (M-CBT): This specialized form of CBT focuses on the particular cognitive distortions and behavioral patterns associated with methamphetamine use, including the intense cravings and anhedonia that often characterize early recovery.
• Integrated CBT for Co-occurring Disorders: Given the high rates of co-occurring mental health conditions among people with methamphetamine use disorder, integrated approaches that simultaneously address both substance use and mental health symptoms have gained traction.
• Trauma-Informed CBT: Recognizing the high prevalence of trauma histories among individuals with methamphetamine use disorder, trauma-informed adaptations of CBT have been developed that address both substance use and trauma symptoms concurrently.

Research published in early 2025 has shown that these tailored CBT approaches, when delivered with fidelity, can significantly improve treatment retention and reduce methamphetamine use compared to standard treatment approaches.

Contingency Management (CM) and Incentive-Based Models

Contingency Management remains one of the most empirically supported treatments for methamphetamine use disorder. The latest treatments for methamphetamine use disorder have seen several innovations in CM implementation:

• Scalable CM Models: New approaches to CM have been developed that reduce the cost and administrative burden, making implementation more feasible across diverse treatment settings.
• Technology-Enhanced CM: Digital platforms now allow for remote monitoring of abstinence and automated delivery of incentives, expanding the reach of CM beyond traditional clinical settings.
• Graduated Reinforcement Schedules: Refined CM protocols incorporate graduated reinforcement schedules that adjust the magnitude of incentives based on duration of abstinence, potentially enhancing long-term outcomes.

The ASCME Trial (Addition of high-dose stimulant and engagement-focused Contingency management for the management of MEthamphetamine use disorder), launched in 2025, is evaluating the efficacy of contingency management both alone and in combination with pharmacotherapy. This landmark study, led by the Centre for Addiction and Mental Health (CAMH), represents one of the largest clinical trials ever conducted for methamphetamine use disorder.

Mobile and Digital Therapeutic Tools

The latest treatments for methamphetamine use disorder increasingly leverage digital technologies to extend the reach and impact of behavioral interventions:

• Recovery Support Apps: Specialized smartphone applications provide on-demand coping skills, craving management techniques, and connection to peer support.
• Virtual Reality Exposure Therapy: VR-based interventions that simulate high-risk situations allow individuals to practice coping skills in realistic but safe environments.
• Digital Therapeutic Programs: FDA-authorized digital therapeutics specifically designed for stimulant use disorders have emerged, offering evidence-based interventions through interactive digital platforms.
• Telehealth Delivery: Remote delivery of behavioral treatments has expanded access to care, particularly for individuals in rural or underserved areas.

These digital approaches represent an important frontier in the latest treatments for methamphetamine use disorder, potentially addressing barriers to care while maintaining therapeutic effectiveness.

Pharmacological Advances and Combination Therapies

While no medications have yet received FDA approval specifically for methamphetamine use disorder, significant advances in pharmacotherapy research have occurred in recent years. The latest treatments for methamphetamine use disorder include several promising pharmacological approaches.

Two-Drug Therapy: Naltrexone + Bupropion

One of the most significant developments in the latest treatments for methamphetamine use disorder is the combination of naltrexone and bupropion. This approach has shown promising results in clinical trials:

• The ADAPT-2 trial (Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder) demonstrated that the combination of extended-release injectable naltrexone and oral bupropion was significantly more effective than placebo in reducing methamphetamine use.
• A 2025 study at St Vincent’s Hospital, Sydney, investigated an oral combination of naltrexone and bupropion, finding it to be a feasible and safe treatment option for methamphetamine use disorder.

The mechanism of action for this combination appears multifaceted:

• Naltrexone, an opioid receptor antagonist, may reduce the rewarding effects of methamphetamine and decrease cravings by modulating dopamine release in the reward pathway.
• Bupropion, a norepinephrine-dopamine reuptake inhibitor with antidepressant properties, may help address dopamine deficiency during early abstinence and alleviate depressive symptoms.

Recent research has provided insights into how this combination works. A 2025 study found that early reduction in depressive symptom severity with naltrexone-bupropion treatment was associated with a higher likelihood of reduced methamphetamine use. This finding suggests that the antidepressant effects of bupropion may be an important mechanism through which the combination therapy exerts its beneficial effects.

Building on these promising results, several clinical trials are currently underway to further evaluate this combination therapy, including studies examining different dosing regimens and formulations.

Other Pharmacological Approaches Under Investigation

Several other medications are being investigated as potential treatments for methamphetamine use disorder:

• Mirtazapine: This antidepressant has shown some promise in reducing methamphetamine use, particularly among specific populations.
• N-acetylcysteine (NAC): This antioxidant may help restore glutamate homeostasis disrupted by chronic methamphetamine use, potentially reducing cravings and preventing relapse.
• Modafinil: This wake-promoting agent with distinct mechanisms from typical stimulants has shown some promise in early trials.
• Selective Serotonin Reuptake Inhibitors (SSRIs): These medications are being investigated for their potential to address co-occurring depression and anxiety in methamphetamine users.

While these approaches have shown varying levels of promise, none has yet demonstrated the consistent efficacy needed for FDA approval. The latest treatments for methamphetamine use disorder continue to explore these and other pharmacological options, often in combination with behavioral interventions.

Substitution and Maintenance Approaches

A significant development in the latest treatments for methamphetamine use disorder is the exploration of stimulant substitution therapy, similar to approaches used for opioid use disorder.

Research into High-Dose Stimulant Substitution

The concept of stimulant substitution therapy involves providing a pharmaceutical-grade stimulant medication to replace illicit methamphetamine use, potentially reducing harm and stabilizing patients enough to engage in comprehensive treatment.

The ASCME Trial, launched in 2025, represents a major advancement in this area. This landmark study is evaluating lisdexamfetamine (brand name Vyvanse), a medication approved for ADHD treatment, as a potential substitution therapy for methamphetamine use disorder.

Key aspects of this approach include:

• Pharmacological Rationale: Lisdexamfetamine is a prodrug that converts to dextroamphetamine in the body, providing a steady, controlled release of amphetamine that may reduce cravings for methamphetamine while avoiding the extreme highs and lows associated with illicit use.
• Harm Reduction Potential: By providing a pharmaceutical-grade stimulant with known purity and dosage, this approach may reduce risks associated with illicit methamphetamine use, including exposure to contaminants and infectious disease transmission.
• Engagement in Treatment: Stabilization on a prescribed stimulant may increase patients’ ability to engage in behavioral treatments and address psychosocial factors contributing to their substance use.

The ASCME Trial is examining both lisdexamfetamine alone and in combination with contingency management, representing a comprehensive approach to treatment that addresses both biological and behavioral aspects of addiction.

Challenges and Controversies

While stimulant substitution therapy shows promise, it also faces significant challenges:

• Regulatory Hurdles: The prescription of controlled stimulants for addiction treatment faces substantial regulatory barriers.
• Diversion Concerns: There are legitimate concerns about the potential for prescribed stimulants to be diverted for non-medical use.
• Theoretical Debates: Some addiction specialists question whether providing a similar class of drug is the optimal approach for stimulant use disorders.

Despite these challenges, the latest treatments for methamphetamine use disorder increasingly recognize the potential value of substitution approaches, particularly for individuals who have not responded to other treatment modalities.

Adjunctive & Novel Interventions

Beyond traditional behavioral and pharmacological approaches, the latest treatments for methamphetamine use disorder include several innovative adjunctive interventions that show promise for enhancing treatment outcomes.

Exercise-Based Treatment Models

Exercise has emerged as a potentially valuable adjunctive treatment for methamphetamine use disorder:

• Neurobiological Benefits: Regular exercise promotes the release of endorphins and increases dopamine sensitivity, potentially addressing the reward dysregulation associated with methamphetamine addiction.
• Stress Reduction: Exercise has well-documented stress-reducing effects, which may help manage the stress-induced cravings common in early recovery.
• Structured Activity: Exercise programs provide structure and healthy alternative activities to fill the void left by discontinued drug use.

Several clinical trials are currently evaluating structured exercise programs as adjuncts to standard treatment for methamphetamine use disorder, with preliminary results suggesting benefits for craving reduction, mood improvement, and cognitive recovery.

Emerging Interest in Psychedelic Pathways

One of the most innovative areas in the latest treatments for methamphetamine use disorder is the exploration of psychedelic-assisted therapy:

• Psilocybin Research: Early-stage research is investigating whether psilocybin-assisted therapy might help address the underlying psychological factors contributing to methamphetamine addiction.
• Ketamine Studies: A multisite study of ketamine for methamphetamine use disorder (NCT06496750) is currently underway, building on findings that suggest ketamine’s rapid antidepressant effects might help reduce methamphetamine use.
• MDMA-Assisted Therapy: For individuals with co-occurring PTSD and methamphetamine use disorder, MDMA-assisted therapy is being explored as a potential approach to address trauma that may underlie substance use.

These approaches typically involve a limited number of psychedelic sessions integrated with psychotherapy, rather than ongoing medication. While research in this area is still preliminary, interest has grown substantially as part of the broader psychedelic renaissance in mental health treatment.

Neuromodulation and Brain-Targeted Techniques

Non-invasive brain stimulation techniques represent another frontier in the latest treatments for methamphetamine use disorder, targeting the neural circuits disrupted by chronic methamphetamine use.

Experimental Use of rTMS

Repetitive Transcranial Magnetic Stimulation (rTMS) is being investigated as a treatment for methamphetamine use disorder:

• Targeting Reward Circuitry: rTMS protocols typically target the dorsolateral prefrontal cortex, which plays a key role in executive function and is connected to reward circuitry disrupted by methamphetamine use.
• Craving Reduction: Several studies have shown that rTMS can temporarily reduce cravings for various substances, including methamphetamine.
• Cognitive Enhancement: rTMS may help improve cognitive functions impaired by chronic methamphetamine use, potentially enhancing patients’ ability to benefit from cognitive-behavioral interventions.

Research published in early 2025 has identified potential biomarkers that might predict responsiveness to rTMS treatment, potentially allowing for more personalized application of this technology.

Other Neuromodulation Approaches

Additional neuromodulation techniques under investigation include:

• Transcranial Direct Current Stimulation (tDCS): This non-invasive technique uses low-intensity direct current to modulate neuronal activity and is being studied for its potential to reduce cravings and improve cognitive function.
• Deep Brain Stimulation (DBS): While highly invasive and still experimental for addiction treatment, DBS targets specific brain regions involved in addiction and is being explored for severe, treatment-resistant cases.
• Neurofeedback: This technique trains individuals to self-regulate brain activity associated with craving and impulse control, potentially enhancing the ability to resist methamphetamine use.

These approaches represent the cutting edge of the latest treatments for methamphetamine use disorder, though most remain in experimental stages and are not yet widely available in clinical practice.

Future Horizons

As we look toward the future of treatment for methamphetamine use disorder, several promising developments are on the horizon that may significantly impact clinical practice.

How Ongoing Large Trials Could Shift Clinical Practice

Several large-scale clinical trials currently underway have the potential to transform treatment approaches:

• The ASCME Trial: This landmark study evaluating lisdexamfetamine and contingency management could establish a new standard of care if results are positive.
• Naltrexone-Bupropion Studies: Ongoing research into different formulations and dosing regimens of this promising combination could lead to FDA approval and wider clinical implementation.
• Digital Therapeutic Validation Studies: Large-scale trials of digital therapeutics specifically designed for methamphetamine use disorder could establish these tools as evidence-based treatment options.

The results of these trials, expected in late 2025 and 2026, may significantly influence treatment guidelines and clinical practice.

Importance of Combining Behavioral and Pharmacological Strategies

The latest treatments for methamphetamine use disorder increasingly recognize that optimal outcomes likely require integrated approaches that combine:

• Pharmacological interventions to address the neurobiological aspects of addiction
• Behavioral therapies to develop coping skills and address psychological factors
• Psychosocial supports to address environmental triggers and social determinants of health

Research consistently shows that combined approaches yield better outcomes than either pharmacological or behavioral interventions alone, highlighting the importance of comprehensive treatment models.

Role of Personalized Medicine and Objective Biomarkers

The future of methamphetamine use disorder treatment is likely to be increasingly personalized, with treatment selection guided by individual characteristics:

• Genetic Factors: Research into pharmacogenomics may help identify which individuals are most likely to respond to specific medications.
• Neuroimaging Biomarkers: Brain imaging studies are identifying patterns of neural activity that may predict treatment response.
• Psychological Profiles: Different psychological characteristics may predict better responses to certain behavioral approaches.

A 2025 study found that early changes in depressive symptoms with naltrexone-bupropion treatment were associated with subsequent reduction in methamphetamine use, suggesting that monitoring depressive symptoms could help identify those most likely to benefit from this approach.

Challenges and Barriers

Despite the progress in developing the latest treatments for methamphetamine use disorder, significant challenges remain in translating research advances into improved outcomes.

Lack of FDA-Approved Drugs

The absence of FDA-approved medications specifically for methamphetamine use disorder remains a significant barrier:

• Limited Treatment Options: Without approved medications, clinicians must rely on off-label use of medications approved for other conditions.
• Insurance Coverage Challenges: Off-label prescribing often faces reimbursement barriers, limiting access to potentially beneficial treatments.
• Research Funding Gaps: The lack of approved treatments reflects historical underinvestment in medication development for stimulant use disorders.

Efforts to address this gap include the FDA’s commitment to considering novel endpoints for clinical trials of methamphetamine use disorder treatments, potentially streamlining the approval process.

Issues with Treatment Access, Stigma, and Relapse Prevention

Beyond the development of effective treatments, numerous systemic barriers affect treatment outcomes:

• Geographic Disparities: Treatment access remains limited in many regions, particularly rural areas.
• Stigma: Persistent stigma surrounding methamphetamine use disorder discourages treatment-seeking and affects the quality of care received.
• Workforce Shortages: Many regions face shortages of addiction treatment specialists trained in the latest evidence-based approaches.
• Relapse Prevention Challenges: The chronic, relapsing nature of methamphetamine use disorder necessitates long-term support that is often unavailable in current treatment systems.

Addressing these barriers requires not only the development of the latest treatments for methamphetamine use disorder but also systemic changes to how treatment is delivered and financed.

Conclusion

The landscape of treatments for methamphetamine use disorder in 2025-2026 represents a field in transition, with promising developments emerging against a backdrop of persistent challenges. The latest treatments for methamphetamine use disorder span a continuum from refinements of established behavioral approaches to innovative pharmacological combinations and cutting-edge neuromodulation techniques.

Several developments stand out as particularly promising:

• The combination of naltrexone and bupropion has demonstrated efficacy in reducing methamphetamine use, with ongoing research exploring optimal implementation.
• High-dose stimulant substitution therapy, particularly with lisdexamfetamine, is being rigorously evaluated in large-scale clinical trials like the ASCME Trial.
• Digital therapeutics and technology-enhanced behavioral interventions are expanding access to evidence-based treatments.
• Novel approaches, including psychedelic-assisted therapy and neuromodulation techniques, offer new avenues for addressing treatment-resistant cases.

Despite these advances, significant gaps remain. The lack of FDA-approved medications specifically for methamphetamine use disorder continues to limit treatment options, while systemic barriers to treatment access persist across many regions.

Looking forward, the integration of pharmacological, behavioral, and psychosocial approaches, guided by principles of personalized medicine, offers the most promising path toward improved outcomes. Continued investment in research, coupled with efforts to address systemic barriers to treatment, will be essential to translate the latest treatments for methamphetamine use disorder into meaningful improvements in the lives of those affected by this challenging condition.

FAQs About Treatments for Methamphetamine Use Disorder

Are there any FDA-approved treatments for methamphetamine use disorder?

As of 2025, there are no FDA-approved medications specifically for methamphetamine use disorder. However, several medications and combination therapies are showing promise in clinical trials, including the combination of naltrexone and bupropion, which has demonstrated efficacy in reducing methamphetamine use in rigorous studies.

What is the most effective current treatment for methamphetamine addiction?

The most effective approach currently combines behavioral therapies (particularly Cognitive Behavioral Therapy and Contingency Management) with appropriate supportive care. For many individuals, the addition of pharmacological treatments such as the naltrexone-bupropion combination may enhance outcomes, though these are still considered experimental.

How long does treatment for methamphetamine use disorder typically last?

Methamphetamine use disorder is a chronic condition that typically requires long-term management. While acute treatment programs may last 1-3 months, ongoing support and relapse prevention are often needed for a year or more. The latest treatments for methamphetamine use disorder increasingly emphasize the importance of long-term recovery support.

Can methamphetamine-induced brain damage be reversed with treatment?

Research suggests that some methamphetamine-induced brain changes may partially recover with sustained abstinence. Emerging evidence indicates that certain treatments, including exercise programs and cognitive remediation therapies, may accelerate this recovery process. However, complete reversal of all changes is not guaranteed, highlighting the importance of early intervention.

What role does family support play in methamphetamine addiction treatment?

Family involvement can significantly enhance treatment outcomes by improving social support, reducing environmental triggers, and helping maintain motivation for recovery. Many of the latest treatments for methamphetamine use disorder incorporate family therapy or education components to leverage this important resource.